Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (6)

Search Parameters:
Authors = Michel G. Bergeron

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
5 pages, 188 KiB  
Editorial
Advances in the Management of Infectious Diseases
by Rabeea F. Omar, Sylvie Trottier, Sachiko Sato, Marc Ouellette and Michel G. Bergeron
Infect. Dis. Rep. 2025, 17(2), 26; https://doi.org/10.3390/idr17020026 - 14 Mar 2025
Viewed by 1026
Abstract
The landscape of infectious diseases has dramatically evolved since the 1970s and the advent of antimicrobials, which heralded a new era in medical history [...] Full article
(This article belongs to the Special Issue Prevention, Diagnosis and Treatment of Infectious Diseases)
12 pages, 778 KiB  
Review
Tackling Infectious Diseases with Rapid Molecular Diagnosis and Innovative Prevention
by Rabeea F. Omar, Maurice Boissinot, Ann Huletsky and Michel G. Bergeron
Infect. Dis. Rep. 2024, 16(2), 216-227; https://doi.org/10.3390/idr16020017 - 5 Mar 2024
Cited by 3 | Viewed by 6131
Abstract
Infectious diseases (IDs) are a leading cause of death. The diversity and adaptability of microbes represent a continuing risk to health. Combining vision with passion, our transdisciplinary medical research team has been focussing its work on the better management of infectious diseases for [...] Read more.
Infectious diseases (IDs) are a leading cause of death. The diversity and adaptability of microbes represent a continuing risk to health. Combining vision with passion, our transdisciplinary medical research team has been focussing its work on the better management of infectious diseases for saving human lives over the past five decades through medical discoveries and innovations that helped change the practice of medicine. The team used a multiple-faceted and integrated approach to control infectious diseases through fundamental discoveries and by developing innovative prevention tools and rapid molecular diagnostic tests to fulfill the various unmet needs of patients and health professionals in the field of ID. In this article, as objectives, we put in context two main research areas of ID management: innovative infection prevention that is woman-controlled, and the rapid molecular diagnosis of infection and resistance. We also explain how our transdisciplinary approach encompassing specialists from diverse fields ranging from biology to engineering was instrumental in achieving success. Furthermore, we discuss our vision of the future for translational research to better tackle IDs. Full article
(This article belongs to the Special Issue Prevention, Diagnosis and Treatment of Infectious Diseases)
Show Figures

Figure 1

18 pages, 989 KiB  
Perspective
Antimicrobial Resistance in the Environment: Towards Elucidating the Roles of Bioaerosols in Transmission and Detection of Antibacterial Resistance Genes
by Paul B. L. George, Florent Rossi, Magali-Wen St-Germain, Pierre Amato, Thierry Badard, Michel G. Bergeron, Maurice Boissinot, Steve J. Charette, Brenda L. Coleman, Jacques Corbeil, Alexander I. Culley, Marie-Lou Gaucher, Matthieu Girard, Stéphane Godbout, Shelley P. Kirychuk, André Marette, Allison McGeer, Patrick T. O’Shaughnessy, E. Jane Parmley, Serge Simard, Richard J. Reid-Smith, Edward Topp, Luc Trudel, Maosheng Yao, Patrick Brassard, Anne-Marie Delort, Araceli D. Larios, Valérie Létourneau, Valérie E. Paquet, Marie-Hélène Pedneau, Émilie Pic, Brooke Thompson, Marc Veillette, Mary Thaler, Ilaria Scapino, Maria Lebeuf, Mahsa Baghdadi, Alejandra Castillo Toro, Amélia Bélanger Cayouette, Marie-Julie Dubois, Alicia F. Durocher, Sarah B. Girard, Andrea Katherín Carranza Diaz, Asmaâ Khalloufi, Samantha Leclerc, Joanie Lemieux, Manuel Pérez Maldonado, Geneviève Pilon, Colleen P. Murphy, Charly A. Notling, Daniel Ofori-Darko, Juliette Provencher, Annabelle Richer-Fortin, Nathalie Turgeon and Caroline Duchaineadd Show full author list remove Hide full author list
Antibiotics 2022, 11(7), 974; https://doi.org/10.3390/antibiotics11070974 - 19 Jul 2022
Cited by 12 | Viewed by 7602
Abstract
Antimicrobial resistance (AMR) is continuing to grow across the world. Though often thought of as a mostly public health issue, AMR is also a major agricultural and environmental problem. As such, many researchers refer to it as the preeminent One Health issue. Aerial [...] Read more.
Antimicrobial resistance (AMR) is continuing to grow across the world. Though often thought of as a mostly public health issue, AMR is also a major agricultural and environmental problem. As such, many researchers refer to it as the preeminent One Health issue. Aerial transport of antimicrobial-resistant bacteria via bioaerosols is still poorly understood. Recent work has highlighted the presence of antibiotic resistance genes in bioaerosols. Emissions of AMR bacteria and genes have been detected from various sources, including wastewater treatment plants, hospitals, and agricultural practices; however, their impacts on the broader environment are poorly understood. Contextualizing the roles of bioaerosols in the dissemination of AMR necessitates a multidisciplinary approach. Environmental factors, industrial and medical practices, as well as ecological principles influence the aerial dissemination of resistant bacteria. This article introduces an ongoing project assessing the presence and fate of AMR in bioaerosols across Canada. Its various sub-studies include the assessment of the emissions of antibiotic resistance genes from many agricultural practices, their long-distance transport, new integrative methods of assessment, and the creation of dissemination models over short and long distances. Results from sub-studies are beginning to be published. Consequently, this paper explains the background behind the development of the various sub-studies and highlight their shared aspects. Full article
(This article belongs to the Special Issue Antimicrobial Resistance and Environmental Health)
Show Figures

Figure 1

8 pages, 2398 KiB  
Article
Complete Genome Sequences of Klebsiella michiganensis and Citrobacter farmeri, KPC-2-Producers Serially Isolated from a Single Patient
by Jehane Y. Abed, Maxime Déraspe, Ève Bérubé, Matthew D’Iorio, Ken Dewar, Maurice Boissinot, Jacques Corbeil, Michel G. Bergeron and Paul H. Roy
Antibiotics 2021, 10(11), 1408; https://doi.org/10.3390/antibiotics10111408 - 18 Nov 2021
Cited by 7 | Viewed by 2899
Abstract
Carbapenemase-producing Enterobacterales, including KPC-2 producers, have become a major clinical problem. During an outbreak in Quebec City, Canada, KPC-2-producing Klebsiella michiganensis and Citrobacter farmeri were isolated from a patient six weeks apart. We determined their complete genome sequences. Both isolates carried nearly identical [...] Read more.
Carbapenemase-producing Enterobacterales, including KPC-2 producers, have become a major clinical problem. During an outbreak in Quebec City, Canada, KPC-2-producing Klebsiella michiganensis and Citrobacter farmeri were isolated from a patient six weeks apart. We determined their complete genome sequences. Both isolates carried nearly identical IncN2 plasmids with blaKPC-2 on a Tn4401b element. Both strains also carried IncP1 plasmids, but that of C. farmeri did not carry a Beta-lactamase gene, whereas that of K. michiganensis carried a second copy of blaKPC-2 on Tn4401b. These results suggest recent plasmid transfer between the two species and a recent transposition event. Full article
(This article belongs to the Special Issue Carbapenemase-Producing Enterobacterales)
Show Figures

Figure 1

14 pages, 1084 KiB  
Review
The GenePOC Platform, a Rational Solution for Extreme Point-of-Care Testing
by Luc Bissonnette and Michel G. Bergeron
Micromachines 2016, 7(6), 94; https://doi.org/10.3390/mi7060094 - 24 May 2016
Cited by 26 | Viewed by 9543
Abstract
Extreme point-of-care (POC) testing for infections, as performed (endured) in low-resource settings, developing countries, tropical areas, or in conditions following emergency crises or natural disasters, must be undertaken under environmental, logistic, and societal conditions which impose a significant deal of stress on local [...] Read more.
Extreme point-of-care (POC) testing for infections, as performed (endured) in low-resource settings, developing countries, tropical areas, or in conditions following emergency crises or natural disasters, must be undertaken under environmental, logistic, and societal conditions which impose a significant deal of stress on local human populations and healthcare providers. For disease diagnostics or management, simple and robust biomedical equipment and reagents are required and needed. This chapter aims to overview some of these stresses (requirements) and intends to describe some of the solutions already engineered at the heart of centripetal (centrifugal) microfluidic platforms such as that of GenePOC Inc. to enable rapid, robust, and reproducible nucleic acid-based diagnostics of infectious diseases, to better control the morbidity and mortality of infections and the expanding threat posed by antimicrobial resistance. Full article
(This article belongs to the Special Issue Centrifugal (Compact-Disc) Microfluidics for Extreme POC)
Show Figures

Graphical abstract

21 pages, 236 KiB  
Review
Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies
by Luc Bissonnette and Michel G. Bergeron
J. Pers. Med. 2012, 2(2), 50-70; https://doi.org/10.3390/jpm2020050 - 2 May 2012
Cited by 53 | Viewed by 16019
Abstract
Infectious disease management essentially consists in identifying the microbial cause(s) of an infection, initiating if necessary antimicrobial therapy against microbes, and controlling host reactions to infection. In clinical microbiology, the turnaround time of the diagnostic cycle (>24 hours) often leads to unnecessary suffering [...] Read more.
Infectious disease management essentially consists in identifying the microbial cause(s) of an infection, initiating if necessary antimicrobial therapy against microbes, and controlling host reactions to infection. In clinical microbiology, the turnaround time of the diagnostic cycle (>24 hours) often leads to unnecessary suffering and deaths; approaches to relieve this burden include rapid diagnostic procedures and more efficient transmission or interpretation of molecular microbiology results. Although rapid nucleic acid-based diagnostic testing has demonstrated that it can impact on the transmission of hospital-acquired infections, we believe that such life-saving procedures should be performed closer to the patient, in dedicated 24/7 laboratories of healthcare institutions, or ideally at point of care. While personalized medicine generally aims at interrogating the genomic information of a patient, drug metabolism polymorphisms, for example, to guide drug choice and dosage, personalized medicine concepts are applicable in infectious diseases for the (rapid) identification of a disease-causing microbe and determination of its antimicrobial resistance profile, to guide an appropriate antimicrobial treatment for the proper management of the patient. The implementation of point-of-care testing for infectious diseases will require acceptance by medical authorities, new technological and communication platforms, as well as reimbursement practices such that time- and life-saving procedures become available to the largest number of patients. Full article
(This article belongs to the Special Issue Recent Advances in Personalized Medicine)
Show Figures

Figure 1

Back to TopTop